Company intelligence / Profile preview

Remedy Meds

United States

Ownership: Private
Development stage: Other

Overview

Remedy Meds operates a commercial telehealth program providing GLP-1–based pharmacologic therapy (including compounded semaglutide and tirzepatide as well as branded products when available) combined with clinician-led virtual care for obesity, weight management, and related metabolic conditions.[3] It reports large-scale member use and self-reported weight loss outcomes but does not run its own drug-development clinical trials.[3]

Therapeutic areas: EndocrinologyMetabolic Disorders
Modalities: Small moleculeHormone
Industry: Non-Academic Healthcare

Partnerships

Compounding pharmacies in the United States supplying compounded GLP-1 medicines[3]Acquisition agreement to purchase Thirty Madison, a US telehealth company, for just over $500 million, broadening its virtual care and pharmacy footprint[2][4]

Beyond the preview

Go deeper on Remedy Meds.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Remedy Meds.

Explore the full profile